CareDx (CDNA) Investor Day 2024 summary

Strategic Vision and Market Positioning

• Focus on unlocking growth in current and future product portfolios, positioning as a leading technology provider in transplantation and adjacent markets.

• Emphasis on a holistic healthcare services model, cross-selling solutions, and leveraging a concentrated market to lower customer acquisition costs.

• Four strategic priorities: profitable growth, operational excellence, expanding into Transplant+, and elevating performance culture.

• Refocused on customer-centricity, shifting from inward sales to enhancing customer experience and engagement.

• Building on a strong, passionate team with deep transplantation connections and a $240M cash position with no debt.

Financial Guidance and Growth Targets

• Targeting $500M+ in revenue by 2027, up from $324M in 2024, representing a 15% three-year CAGR.

• Adjusted EBITDA margin goal of 20% by 2027, with operating expenses growing at half the rate of revenue.

• Gross margin expected to exceed 70% by 2027, placing the company in the top tier of its peer group.

• Plan to add over $100M in cash over three years, with no need for additional capital or debt.

• Strategic capital allocation focused on M&A, core business investment, and potential share buybacks.

Commercial and Operational Execution

• Four building blocks for growth: leveraging transplant volume growth, driving greater portfolio adoption, improving patient adherence, and accelerating product launches.

• Account management approach increases customer stickiness and multiplies revenue per center.

• Integration of digital tools and software to streamline ordering, improve patient and physician experience, and drive operational efficiency.

• Use of AI and automation to reduce costs, improve turnaround times, and consolidate business processes.

• Operational focus on scaling global operations, maintaining supply chain discipline, and maximizing margin improvement.